ClinicalTrials.gg
RecruitingNCT07139899Updated Nov 18, 2026

Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma

An observational study in Severe Asthma, sponsored by Bastiaan Driehuys. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Bastiaan Driehuys · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 18, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.

Planned enrollment
313th of 330
5 · median 112
Started
2025
with 36 others
Observational
335 of 1,696
34 open now
Primary completion
2026-11
later than 38 of 184 live
Registered
1,637th of 1,696
by date

Among the 1,696 studies in Asthma with a site in United States, this one is the 313th largest by planned enrollment of the 330 observational ones that give a count, is one of 37 that started in 2025, is one of 335 observational ones, reaches primary completion later than 38 of the 184 other live ones, and was the 1,637th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,696 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with severe asthma. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.

03

Conditions studied

  • Severe Asthma

Browse trials for

Keywords

  • xenon
  • asthma
  • mucus
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with High T2 Severe Asthma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adequate completion of process with written documentation
  • Patients 18 - 65 years old
  • Physician diagnosis of asthma for > 1 year
  • Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs within previous 30 days of enrollment
  • All racial/ethnic backgrounds may participate
  • Blood eosinophil count > 300 cells/μL OR muco-obstructive disease in the judgment of the referring physician
  • Smoking history \<10 pack years
  • No smoking history (including vapes, cigar, or marijuana use) in the last 3 months
  • About to initiate asthma therapy with either dupilumab, tezepelumab, or benralizumab as part of their standard of care

Exclusion criteria

Exclusion Criteria:

  • Respiratory tract infection within the 4 weeks prior to Visit 1
  • (BMI) > 30 at Visit 1
  • One-time doses such as intra-articular injections require a 4-week prior to Visit 1
  • Asthma-related ER visit within the previous 4 weeks of Visit 1 or at any time while on the study
  • Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.)
  • Resting O2 saturation \<90% with maximum supplemental O2 delivered by nasal cannula
  • Positive urine pregnancy test at Visit 1 or at any time while on the study
  • Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study
  • Unable or unlikely to complete study assessments in the opinion of the Investigator
  • Study intervention poses undue risk to patient in the opinion of the Investigator
  • Conditions that will prohibit MRI scanning determined by the MRI safety screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5 participants (estimated)
Patient registry
No

Interventions

  • Combination productHyperpolarized Xenon 129

    Pulmonary magnetic resonance imaging using hyperpolarized xenon-129 gas as an inhaled contrast agent

06

What researchers measure

Primary outcomes

  1. Ventilation Defect in Mucus-blocked regions

    The primary endpoint of this study is the ventilation defect percent (VDP; measured by Xe-MRI) in regions of the lungs that are downstream of mucus plugs (identified on CT imaging).

    Time frame: 12 weeks

Secondary outcomes

  1. Change in VDP

    The change in VDP downstream of mucus plugs 4 weeks following initiation of biologic therapy.

    Time frame: 4 weeks

  2. Long term change in VDP

    Change in VDP downstream of mucus plugs 12 weeks following initiation of biologic therapy

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Images from participants will be shared, alongside pulmonary function testing data and basic demographics.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 12 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2025
First posted
Aug 24, 2025
StartActual
Nov 17, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Sep 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedBlood eosinophil count > 300 cells/μL OR muco-obstructive disease in the judgment of the referring physician
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedBlood eosinophil count > 300 cells/μL OR muco-obstructive disease in the judgment of the referring physician
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07139899
Lead sponsor
Bastiaan Driehuys
Collaborators
University of Kansas Medical Center, Polarean, Inc.
Responsible party
Bastiaan Driehuys (Professor of Radiology, Duke University) — Sponsor-investigator
First posted
Aug 24, 2025
Start date
Nov 17, 2025
Primary completion
Nov 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

David Mummy, PhD
Contact
david.mummy@duke.edu
9846847783
Bastiaan Driehuys, PhD
Contact
bastiaan.driehuys@duke.edu
919-684-7786
David Mummy, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion